Media Articles Related to Razadyne (Galantamine)
The future of gene therapy for Alzheimer's disease
Source: Genetics News From Medical News Today [2014.07.24]
Hypoxia-inducible factor 1 (HIF-1) attenuates amyloid-beta protein neurotoxicity and decreases apoptosis induced by oxidative stress or hypoxia in cortical neurons.
Amyloid plaque in Alzheimer's disease may affect remote regions of the brain
Source: Neurology / Neuroscience News From Medical News Today [2014.07.24]
In Alzheimer's disease, accumulation of amyloid plaque in the brain is believed to play an important role in many characteristic disease symptoms, including memory loss and other mental state changes.
Prediction Update: Alzheimer's Disease 2
Source: MedPage Today Cardiovascular [2014.07.24]
(MedPage Today) -- In January, we asked three noted neurologists, "What do you anticipate will be the most important clinical development in Alzheimer's disease in 2014?" Now, at the half-year mark, we check in with them again to ask how their predictions are holding up.
Neuronal edema in Alzheimer's disease rats reduced by acupuncture and moxibustion
Source: Complementary Medicine / Alternative Medicine News From Medical News Today [2014.07.21]
Aberrant Wnt signaling is possibly related to the pathological changes in Alzheimer's disease (AD).
Alzheimer's disease not prevented by B vitamins
Source: Seniors / Aging News From Medical News Today [2014.07.17]
Taking B vitamins doesn't slow mental decline as we age, nor is it likely to prevent Alzheimer's disease, conclude Oxford University researchers who have assembled all the best clinical trial data...
Published Studies Related to Razadyne (Galantamine)
Long-term response to galantamine in relation to short-term efficacy data: pooled analysis in patients with mild to moderate Alzheimer's disease. [2011.03]
BACKGROUND: This analysis aimed to identify an operational, clinically relevant definition of response achieved in short-term clinical trials to support the identification of patients with Alzheimer's disease (AD) who would benefit most from long-term galantamine therapy... CONCLUSIONS: Patients who demonstrate improvement, stability, or limited cognitive decline 2-5 months after reaching maintenance doses of galantamine are more likely to experience continued benefit from long-term galantamine therapy.
Galantamine improves sustained attention in chronic cocaine users. [2011.02]
Chronic cocaine users are known to have cognitive deficits that are predictive of poor treatment response. Whether these deficits improve with medications targeting specific cognitive functions has not been examined in previous studies.
Galantamine augmentation of long-acting injectable risperidone for cognitive impairments in chronic schizophrenia. [2011.02]
CONCLUSION: Galantamine showed no ameliorative effects on cognitive measures in this 6month, double-blind study of patients with schizophrenia treated with an assured and stable antipsychotic medication delivery system. Galantamine may not be an appropriate augmentation agent for cognitive impairments in patients with schizophrenia at the dose used. Copyright (c) 2010 Elsevier B.V. All rights reserved.
Cessation versus continuation of galantamine treatment after 12 months of therapy in patients with Alzheimer's disease: a randomized, double blind, placebo controlled withdrawal trial. 
Galantamine improved symptoms in Alzheimer's disease (AD) patients after 5 to 6 months of treatment... Treatment was generally safe and well tolerated.
Galantamine improves sustained attention in chronic cocaine users. 
Chronic cocaine users are known to have cognitive deficits that are predictive of
poor treatment response. Whether these deficits improve with medications
targeting specific cognitive functions has not been examined in previous studies.
Clinical Trials Related to Razadyne (Galantamine)
The Use of Galantamine HBr (Reminyl) in Electroconvulsive Therapy: Impact on Mood and Cognitive Functioning [Active, not recruiting]
The purpose of the study is to see if galantamine HBr (Razadyne) is safe and can help treat
problems with thinking and memory caused by electroconvulsive therapy (ECT).
Effects of Galantamine on Cognition [Recruiting]
Schizophrenia is a chronic disorder with onset of psychosis occurring in late teen early
twenties, with cognitive impairments and negative symptoms frequently emerging much earlier.
Such cognitive impairments and negative symptoms but much milder are also observed in
high-risk groups (such as relatives of schizophrenia patients), who may or may not develop
the full blown psychotic disorder. Our study plans to recruit such non-ill subjects to test
the effects of galantamine on clinical/physiological/cognitive measures. This study serves
several goals: If a drug is found effective in treating subtle deficits, then it will
provide treatment strategy in individuals with schizophrenia spectrum personality disorders
and for early intervention in schizophrenia. In addition, one of the difficulties of
testing a drug on schizophrenia is that patients take other medications (i. e., antipsychotic
drugs) that can change the effects of the test drug. The proposed study will be in subjects
who will not be taking antipsychotic medications. Our study will be carried out in two
sessions, at least one month apart. Subjects will be randomly assigned to the two possible
order of administration: the drug and then placebo, or the placebo and then drug. Subjects
will be given a lead-in 3 days of 4mg/ twice a day of galantamine (or placebo) followed by 8
mg (or placebo) on the 4th day, the day of testing. We will administer a battery of
clinical/cognitive/neurophysiological tests after the 8 mg drug dose.
A Single Dose, Cross-Over Bioequivence Study Comparing Galantamine IR (Immediate Release) Table and Galantmine OS (Oral Solution) in Healthy Volunteers [Completed]
The purpose of this open-label, single dose, two-treatment, two-period, cross-over study is
to evaluate the pharmacokinetic profile and tolerability of galantamine oral solution and
Effects of Galantamine on Smoking Abstinence [Recruiting]
Oxytocin or Galantamine Versus Placebo for the Treatment of Negative Symptoms and Cognitive Impairments in Schizophrenia [Recruiting]
The project is designed to address the following two primary aims:
1. To determine whether adjunctive oxytocin is superior to placebo for the treatment of
persistent negative symptoms, as measured by the SANS total score, in people with
2. To determine whether adjunctive Galantamine is superior to placebo for the treatment of
cognitive impairments, as measured by improvement on a composite neurocognitive score
in people with schizophrenia.
The investigators will also address the following secondary aims:
1. To determine whether people with schizophrenia treated with adjunctive oxytocin,
compared to placebo, will show greater improvement on markers of negative symptom
liability including: social affiliation, facial affect recognition, olfactory
discrimination, initiation of smooth pursuit and latency of internally-driven saccades.
2. To determine whether people with schizophrenia treated with adjunctive Galantamine,
compared to placebo, will show greater improvement on markers of cognitive impairment
liability including: predictive pursuit, P50 sensory gating and visual-spatial working
The investigators will address the following exploratory aims:
1. To determine whether changes in markers of negative symptom liability are correlated
with changes in SANS total score.
2. To determine whether changes in markers of cognitive impairment liability are
correlated with changes in the composite neurocognitive score.
3. To determine the response to oxytocin of all cognition domains assessed by the MATRICS
battery, and to determine the response to Galantamine of all cognition domains assessed
by the MATRICS, which are not included in the primary neurocognitive outcome score.
4. To determine whether there is a differential response of oxytocin and Galantamine on
the SANS total score, composite neurocognitive score, and with the phenotypic measures
of negative symptom and cognitive impairment liability.
5. To determine whether oxytocin and Galantamine are associated with:
- adverse effects on positive or depressive symptoms;
- adverse effects on motor symptoms;
- adverse effects on laboratory and EKG measures;
- increased occurrence of side effects;
- social interest that is independent of sexual desire.